Intratumoral Injection of Autologous CD1c (BDCA-1)+ MyDC, Avelumab, and Ipilimumab Plus Systemic Nivolumab

NCT03707808 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Solid Tumor
Metastases to Soft Tissue

Interventions

DRUG: intratumoral injection of autologous CD1c (BDCA-1)+ myDC
DRUG: Intratumoral injection of ipilimumab and AS01b
DRUG: IV nivolumab

Sponsor

Universitair Ziekenhuis Brussel